Fundraising Fox
Harmony Biosciences
NASDAQ: HRMYUnicorn · $1.4BNorthbrook, US · Founded 2017 · Delaware corporation · 341 employees on LinkedIn · 10 known investors
Find your way into Harmony Biosciences
Sign up to see every warm intro you have to Harmony Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Harmony Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
Founders & leadership
Harmony Biosciences was founded in 2017 by Jeffrey Aronin.
Board
Investors · 10
How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: Paragon Biosciences LLC's portfolio page · Not right? Tell us
How we know: Pivotal Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Valor Equity Partners's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$345M disclosed across 3 rounds · 2017–2019
▶$50MraisedAug 2019 · 30 investors · PharmaceuticalsRule 506(b)
- JACK BECH NIELSENDirector
- MARTIN EDWARDSDirector
- AARON ROYSTONDirector
- DR. ANDREAS WICKIDirector
- WILBUR GANTZ, IIIDirector
- OCTAGON CAPITAL GROUP, LLCPromoter
- JUAN SABATERDirector
- JOHN JACOBSExecutive Officer, Director
- JOHN VITTORIAExecutive Officer
- ANDREW SERAFINExecutive Officer
- JEFFREY ARONINDirector
- ANTONIO GRACIASDirector
- PATRICK MORRISExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- Minimum investment
- $14K
- Sales commissions
- $1M
- Placement agents
- OCTAGON CAPITAL GROUP, LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25MraisedJan 2018 · 2 investors · PharmaceuticalsRule 506(b)
- Patrick MorrisExecutive Officer
- Jeffrey AroninDirector
- Aaron RoystonDirector
- Dr. Andreas WickiDirector
- Jack NielsenDirector
- Robert RepellaExecutive Officer, Director
- Antonio GraciasDirector
- Martin EdwardsDirector
- Juan SabaterDirector
- Wilbur Gantz IIIDirector
- Darien ParhadExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$270MraisedOct 2017 · 29 investors · PharmaceuticalsRule 506(b)
- Patrick MorrisExecutive Officer
- Wilbur Gantz IIIDirector
- Octagon Capital Group, LLCPromoter
- Darien ParhadExecutive Officer
- Juan SabaterDirector
- Martin EdwardsDirector
- Aaron RoystonDirector
- Jeffrey AroninDirector
- Dr. Andreas WickiDirector
- Jack Bech NielsenDirector
- Robert RepellaDirector
- Antonio GraciasDirector
- Offering amount
- $270M
- Amount sold
- $270M
- Minimum investment
- $50K
- Sales commissions
- $5.9M
- Placement agents
- Octagon Capital Group, LLC
- First sale
- Sep 2017
- Incorporated
- Limited Liability Company, Illinois, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 1
Companies working in the same space as Harmony Biosciences.
Frequently asked questions
- What does Harmony Biosciences do?
- Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
- Who founded Harmony Biosciences?
- Harmony Biosciences was founded by Jeffrey Aronin in 2017.
- Who are Harmony Biosciences's investors?
- Harmony Biosciences's investors include Aisling Capital, HBM Healthcare Investments, HBM Partners, Paragon Biosciences LLC, Pivotal Life Sciences, Valor Equity Partners, venBio Partners, Novo Holdings and 2 more.
- How much funding has Harmony Biosciences raised?
- Harmony Biosciences has disclosed $345M raised across 3 rounds.
- Where is Harmony Biosciences headquartered?
- Harmony Biosciences is headquartered in Northbrook, US.